Non-specific inhibitors of the NFκB pathway, including aspirin and aspirin-related drugs, have shown positive therapeutic effects in diabetic patients, indicating the importance of NFκB activation in the development of type 2 diabetes [2], [6], [17], [18], [29]. Here, NFKB1 is linked to type 2 diabetes mellitus.